A Two-Step Synthesis of 1H-Tetrazolyl-1H-1,4-benzonitriles and 1H-Tetrazolyl-benzo[b][1,4]diazepines

Abstract

A two-step synthetic protocol for the title heteroannulated diazepines has been developed. The approach includes a pseudo five-component isocyanide-based condensation reaction between diamines, ketones, isocyanides and trimethylsilyl azide and proceeds in good yields.

diazepine - tetrazole - multicomponent reactions - iso­cyanide

References and Notes

<A NAME="RD76011ST-1A">1a</A> Sternbach LH. J. Med. Chem.  1979,  22:  1 

<A NAME="RD76011ST-1B">1b</A> Lee SC. Park SB. Chem. Commun.  2007,  3714 

<A NAME="RD76011ST-2A">2a</A> Evans BE. Rittle KE. Bock MG. DiPardo RM. Freidinger RM. Whitter WL. Lundell GF. Veber DF. Anderson PS. J. Med. Chem.  1988,  31:  2235 

<A NAME="RD76011ST-2B">2b</A> Herpin TF. Kirk KGV. Salvino JM. Yu ST. Labaudiniere RF. J. Comb. Chem.  2000,  5:  513 

<A NAME="RD76011ST-3A">3a</A> Ohtake Y, and Fukaya Y. inventors; E. Patent,  1 820 799 A1. 

<A NAME="RD76011ST-3B">3b</A> Finch H, Shah P, and Carr RAE. inventors; U.S. Patent,  5 585 376. 

<A NAME="RD76011ST-4">4</A> Tranquillini ME. Cassara PG. Corsi M. Curotto G. Donati D. Finizia G. Pentassuglia G. Polinelli S. Tarzia G. Ursini A. Amsterdam FTMV. Arch. Pharm. (Weinheim, Ger.)  1997,  330:  353 

<A NAME="RD76011ST-5A">5a</A> Kruse H. Drug Dev. Res.  1982,  2:  145 

<A NAME="RD76011ST-5B">5b</A> Ursini A. Capelli AM. Carr RAE. Cassara P. Corsi M. Curcuruto O. Curotto G. Cin MD. Davalli S. Donati D. Feriani A. Finch H. Finizia G. Gaviraghi G. Marien M. Pentassuglia G. Polinelli S. Ratti E. Reggiani A. Tarzia G. Tedesco G. Tranquillini ME. Trist DG. Amsterdam FTMV. J. Med. Chem.  2000,  43:  3596 

<A NAME="RD76011ST-5C">5c</A> Herpin TF. Kirk KGV. Salvino JM. Yu ST. Labaudiniere RF. J. Comb. Chem.  2000,  2:  513 

<A NAME="RD76011ST-5D">5d</A> Cepanec I. Litvic M. Pogorelic I. Org. Process Res. Dev.  2006,  10:  1192 

<A NAME="RD76011ST-5E">5e</A> Zhao HY. Liu G. J. Comb. Chem.  2007,  9:  1164 

<A NAME="RD76011ST-5F">5f</A> Silva RAD. Santra S. Andreana PR. Org. Lett.  2008,  10:  4541 

<A NAME="RD76011ST-5G">5g</A> Butini S. Gabellieri E. Huleatt PB. Campiani G. Franceschini S. Brindisi M. Ros S. Coccone SS. Fiorini I. Novellino E. Giorgi G. Gemma S. J. Org. Chem.  2008,  73:  8458 

<A NAME="RD76011ST-5H">5h</A> Reid W. Stahlofen P. Chem. Ber.  1957,  90:  825 

<A NAME="RD76011ST-6A">6a</A> Slusarchyk WA. Vite G. Yan N. Manne V. Hunt JT. J. Med. Chem.  1999,  42:  5241 

<A NAME="RD76011ST-6B">6b</A> Borisov RS. Polyakov AI. Medvedeva LA. Khrustalev VN. Guranova NI. Voskressensky LG. Org. Lett.  2010,  12:  3894 

<A NAME="RD76011ST-7A">7a</A> Schmidt B. Schieffer B. J. Med. Chem.  2003,  46:  2261 

<A NAME="RD76011ST-7B">7b</A> Bekhit AA. El-Sayed OA. Aboulmagd E. Park JY. Eur. J. Med. Chem.  2004,  39:  249 

<A NAME="RD76011ST-7C">7c</A> Rajasekaran A. Thampi PP. Eur. J. Med. Chem.  2004,  39:  273 

<A NAME="RD76011ST-7D">7d</A> Kozikowski AP. Zhang J. Nan F. Petukhov PA. Grajkowska E. Wroblewski JT. Yamamoto T. Bzdega T. Wroblewska B. Neale J. J. Med. Chem.  2004,  47:  1729 

<A NAME="RD76011ST-7E">7e</A> Upadhayaya RS. Jain S. Sinha N. Kishore N. Chandra R. Arora SK. Eur. J. Med. Chem.  2004,  39:  579 

<A NAME="RD76011ST-7F">7f</A> Faucher A.-M. White PW. Brochu C. Grand-Maitre C. Rancourt J. Fazal G. J. Med. Chem.  2004,  47:  18 

<A NAME="RD76011ST-7G">7g</A> Park H. Merz KM. J. Med. Chem.  2005,  48:  1630 

<A NAME="RD76011ST-7H">7h</A> Bekhit AA. El-Sayed OA. Al-Allaf TAK. Aboul-Enein HY. Kunhi M. Pulicat SM. Al-Hussain K. Al-Khodairy F. Arif J. Eur. J. Med. Chem.  2004,  39:  499 

<A NAME="RD76011ST-8A">8a</A> Biot C. Baver H. Schirmer RH. Davioud-Charvet E. J. Med. Chem.  2004,  47:  5972 

<A NAME="RD76011ST-8B">8b</A> Herr RJ. Bioorg. Med. Chem.  2002,  10:  3379 

<A NAME="RD76011ST-8C">8c</A> KoharaY . Kubo K. Imamiya E. Wada T. Inada Y. Naka T. J. Med. Chem.  1996,  39:  5228 

<A NAME="RD76011ST-8D">8d</A> Schelenz T. Schafer W. J. Prakt. Chem.  2000,  342:  91 

<A NAME="RD76011ST-8E">8e</A> Joo Y.-H. Shreeve JM. Angew. Chem. Int. Ed.  2010,  49:  7320 

<A NAME="RD76011ST-8F">8f</A> Gutmann B. Roduit J.-P. Roberge D. Kappe CO. Angew. Chem. Int. Ed.  2010,  49:  7101 

<A NAME="RD76011ST-8G">8g</A> Kaim LE. Grimaud L. Patil P. Org. Lett.  2011,  13:  1261 

<A NAME="RD76011ST-9">9</A> Butler RN. Tetrazoles, In Comprehensive Heterocyclic Chemistry II   Vol. 4:  Pergamon; Oxford: 1996.  p.621-678  

<A NAME="RD76011ST-10A">10a</A> May BCH. Abell AD. Tetrahedron Lett.  2001,  42:  5641 

<A NAME="RD76011ST-10B">10b</A> Schroeder GM. Marshall S. Wan H. Purandare AV. Tetrahedron Lett.  2010,  51:  1404 

<A NAME="RD76011ST-10C">10c</A> Al-Hourani BJ. Sharma SK. Mane JY. Tuszynski J. Baracos V. Kniess T. Suresh M. Pietzsch J. Wuest F. Bioorg. Med. Chem. Lett.  2011,  21:  1823 

<A NAME="RD76011ST-11">11</A> Nonoshita K, Ogino Y, Ishikawa M, Sakai F, Nakashima H, Nagae Y, Tsukahara D, Arakawa K, Nishimura T, and Eiki J. inventors; PCT Int. Appl. WO  2004-JP19843.  ; Chem. Abstr. 2005, 143, 153371

<A NAME="RD76011ST-12">12</A> Seki M, Tarao Y, Yamada K, Nakao A, Usui Y, and Komatsu Y. inventors; PCT Int. Appl. WO  2005-JP2974.  ; Chem. Abstr. 2005, 143, 266938

<A NAME="RD76011ST-13">13</A> Luo G, Chen L, Degnan AP, Dubowchik GM, Macor JE, Tora GO, and Chaturvedula PV. inventors; PCT Int. Appl. WO  2004-US40721.  ; Chem. Abstr. 2005, 143, 78091

<A NAME="RD76011ST-14">14</A> Miao Z, Sun Y, Nakajima S, Tang D, Wu F, Xu G, Or YS, and Wang Z. inventors; U. S. Pat. Appl. Publ. US  2005153877.  ; Chem. Abstr. 2005, 143, 153709

<A NAME="RD76011ST-15A">15a</A> Duncia JV. Carini DJ. Chiu AT. Johnson AL. Price WA. Wong PC. Wexler RR. Timmermans PBMWM. Med. Res. Rev.  1992,  12:  149 

<A NAME="RD76011ST-15B">15b</A> Smith RD. Duncia JV. Lee RJ. Christ DD. Chiu AT. Carini DJ. Herblin WF. Timmermans PBMWM. Wexler RR. Wong PC. Methods Neurosci.  1993,  13:  258 

<A NAME="RD76011ST-16A">16a</A> Huang R.-Q. Bell-Horner CL. Dibas MI. Covey DF. Drewe JA. Dillon GH. J. Pharmacol. Exp. Ther.  2001,  298:  986 

<A NAME="RD76011ST-16B">16b</A> Jung ME. Lal H. Gatch MB. Neurosci. Biobehav. Rev.  2002,  26:  429 

<A NAME="RD76011ST-17A">17a</A> Daya S. Kaye PT. Mphahlele MJ. Med. Sci. Res.  1996,  24:  137 

<A NAME="RD76011ST-17B">17b</A> Ek F. Manner S. Wistrand L.-G. Frejd T. J. Org. Chem.  2004,  69:  1346 

<A NAME="RD76011ST-18A">18a</A> Forster MO. J. Chem. Soc.  1909,  95:  184 

<A NAME="RD76011ST-18B">18b</A> Schroeter G. Ber. Dtsch. Chem. Ges.  1909,  42:  2336 

<A NAME="RD76011ST-18C">18c</A> von Braun J. Rudolph W. Ber. Dtsch. Chem. Ges. B  1941,  74:  264 

<A NAME="RD76011ST-18D">18d</A> Harvill EK. Herbst RM. Schreiner EC. Roberts CW. J. Org. Chem.  1950,  15:  662 

<A NAME="RD76011ST-19A">19a</A> Wu S. Fluxe A. Sheffer J. Janusz JM. Blass BE. White R. Jackson C. Hedges R. Murawsky M. Fang B. Fadayel GM. Hare M. Djandjighian L. Bioorg. Med. Chem. Lett.  2006,  16:  6213 

<A NAME="RD76011ST-19B">19b</A> Boyko V. Rodik R. Danylyuk O. Tsymbal L. Lampeka Y. Suwinska K. Lipkowski J. Kalchenko V. Tetrahedron  2005,  61:  12282 

<A NAME="RD76011ST-19C">19c</A> Yu KL. Johnson RL. J. Org. Chem.  1987,  52:  2051 

<A NAME="RD76011ST-19D">19d</A> Kennedy LJ. Tetrahedron Lett.  2010,  51:  2010 

<A NAME="RD76011ST-20A">20a</A> Shaabani A. Maleki A. Moghimi-Rad J. J. Org. Chem.  2007,  72:  6309 

<A NAME="RD76011ST-20B">20b</A> Shaabani A. Maleki A. Mofakham H. Moghimi-Rad J. J. Org. Chem.  2008,  73:  3925 

<A NAME="RD76011ST-20C">20c</A> Shaabani A. Maleki A. Mofakham H. Khavasi HR. J. Comb. Chem.  2008,  10:  323 

<A NAME="RD76011ST-20D">20d</A> Shaabani A. Maleki A. Mofakham H. J. Comb. Chem.  2008,  10:  595 

<A NAME="RD76011ST-20E">20e</A> Shaabani A. Maleki A. Hajishaabanha F. Mofakham H. Seyyedhamzeh M. Mahyari M. Weng NgS. J. Comb. Chem.  2010,  12:  186 

<A NAME="RD76011ST-20F">20f</A> Shaabani A. Rezayan AH. Sarvary A. Keshipour S. Ng SW. Org. Lett.  2009,  11:  3342 

<A NAME="RD76011ST-20G">20g</A> Shaabani A. Soleimani E. Rezayan AH. Sarvary A. Khavasi HR. Org. Lett.  2008,  10:  2581 

<A NAME="RD76011ST-20H">20h</A> Shaabani A. Mofakham H. Maleki A. Hajishaabanha F. J. Comb. Chem.  2010,  12:  630 

<A NAME="RD76011ST-21A">21a</A> Multicomponent Reactions   Zhu J. Bienaymé H. Wiley-VCH; Weinheim: 2005. 

<A NAME="RD76011ST-21B">21b</A> Dömling A. Chem. Rev.  2006,  106:  17 

<A NAME="RD76011ST-22A">22a</A> Horiguchi E. Shirai K. Jaung J. Furusyo M. Takagi K. Matsuoka M. Dyes Pigm.  2001,  50:  99 

<A NAME="RD76011ST-22B">22b</A> Shirai K. Matsuoka M. Fukunishi K. Dyes Pigm.  2000,  47:  107 

<A NAME="RD76011ST-22C">22c</A> Handa M. Farida A. Thompson L. Hayashibara C. Sugimori T. Hiromitsu I. Kasuga K. Mol. Cryst. Liq. Cryst. Sci. Technol., Sect. A  2000,  342:  75 

<A NAME="RD76011ST-23A">23a</A> Begland RW. Hartter DR. Jones FN. Sam DJ. Shepperd WA. Webster OW. Weigert FJ. J. Org. Chem.  1974,  39:  2341 

<A NAME="RD76011ST-23B">23b</A> Ohtsuka Y. J. Org. Chem.  1976,  41:  629 

<A NAME="RD76011ST-23C">23c</A> Ohtsuka Y. Tohma E. J. Org. Chem.  1979,  44:  4871 

<A NAME="RD76011ST-23D">23d</A> Mague JT. Eduok EE. J. Chem. Crystallogr.  2000,  30:  311 

<A NAME="RD76011ST-24A">24a</A> Jin T. Kamijo S. Yamamoto Y. Tetrahedron Lett.  2004,  45:  9435 

<A NAME="RD76011ST-24B">24b</A> Kennedy LJ. Tetrahedron Lett.  2010,  51:  2010 

<A NAME="RD76011ST-25">25</A>

Melting points were measured with an Electrothermal 9200 apparatus. Mass spectra were recorded with a Finnigan-MAT 8430 mass spectrometer operating at an ionization potential of 70 eV. IR spectra were recorded with a Shimadzu IR-470 spectrometer. ^¹H NMR spectra were recorded with a Bruker DRX-300 Avance spectrometer at 300.13 MHz; chemical shifts (δ) are reported in units of parts per million(ppm). ^¹H NMR spectra are reported in the order: multiplicity, approximate coupling constant (J value) in hertz (Hz), and integration. ^¹³C NMR spectra were recorded at 75.47 MHz; chemical shifts (δ) are reported in ppm. Elemental analyses were performed with an Elementar Analysensysteme GmbH VarioEL. All the products are new compounds, which were characterized by IR, ^¹H and ^¹³C NMR spectra and Mass spectral data.
Synthesis of 1 H -tetrazolyl-1 H -1,4-diazepine-2,3-dicarbonitriles 6a-g and 1 H -tetrazolyl-benzo[ b ]-[1,4]diazepines 7a-f; General Procedure: A solution of the diamine (1.00 mmol) and ketone (2.20 mmol) in the presence of p-TsOH˙H₂O (0.095 g, 5 mol%) was stirred for 4 h in MeOH (5 mL) at ambient temperature. After completion of the reaction, as indicated by TLC (EtOAc-n-hexane, 3:1), the isocyanide (1.00 mmol) and H₂O (0.50 mL) were added to the reaction mixture. The resulting mixture was stirred for 12 h at ambient temperature. After completion of the reaction, as indicated by TLC (EtOAc-n-hexane, 4:1), the product was filtered off, washed further with H₂O, and then crystallized from acetone to give the 1,4-diazepine derivative.
To a solution of the 1,4-diazepine (0.50 mmol) and pyridine (3.00 mmol) in CH₂Cl₂ (5.00 mL) was added PCl₅ (0.75 mmol) and the resulting mixture was heated to reflux. After 6 h the reaction mixture was cooled to ambient temperature and TMSN₃ (2.00 mmol) was added and stirred for 24 h at ambient temperature. After completion of the reaction, as indicated by TLC (EtOAc-n-hexane, 4:1), the product was filtered off, washed further with H₂O and MeOH, and then crystallized from acetone to give 6a-g and 7a-f.
5-(1-Cyclohexyl-1 H -tetrazol-5-yl)-5,7,7-trimethyl-4,5,6,7-tetrahydro-1 H -1,4-diazepine-2,3-dicarbonitrile (6a): Colorless crystals; mp 229-231 ˚C. IR (KBr): 3350, 3135, 3078, 2940, 2865, 2213, 1656, 1625, 1478, 1390 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.10 (m, 20 H, 5 × CH₂ of c-Hex, 3 × CH₃ and 1 H CH), 2.79 (AB_q, J = 14.2 Hz, 1 H, CH₂), 4.75 (m, 1 H, CH of c-Hex), 5.75 (s, 1 H, NH), 6.78 (s, 1 H, NH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 25.0, 25.3, 30.5, 31.6, 31.8, 33.9, 34.2, 46.5, 54.8, 56.8, 58.1, 106.0, 109.7, 116.3, 116.8, 158.8. MS: m/z = 340 (20) [M]⁺, 258 (15), 189 (55), 173 (20), 153 (20), 133 (100), 111 (15), 83 (20), 56 (65). Anal. Calcd for C₁₇H₂₄N₈: C, 59.98; H, 7.11; N, 32.92. Found: C, 59.92; H, 7.00; N, 32.82.
9a-(1-Cyclohexyl-1 H -tetrazol-5-yl)-1,4,5a,6,7,8,9,9a-octahydrospiro[benzo[ e ][1,4]diazepine-5,1′-cyclohexane]-2,3-dicarbonitrile (6b): Colorless crystals; mp >300 ˚C. IR (KBr): 3345, 3135, 2983, 2935, 2857, 2225, 2206, 1622, 1495, 1454, 1404, 1297 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.10 (m, 28 H, 14 × CH₂ of c-Hex), 2.64 (m, 1 H, CH), 4.69 (m, 1 H, CH of c-Hex), 4.80 (s, 1 H, NH), 6.85 (s, 1 H, NH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 19.0, 20.9, 21.6, 25.0, 25.4, 30.5, 34.2, 34.8, 37.4, 46.2, 49.0, 56.5, 57.9, 59.8, 61.2, 106.1, 110.0, 116.1, 116.5, 161.1. Anal. Calcd for C₂₃H₃₂N₈: C, 65.69; H, 7.67; N, 26.64. Found: C, 65.60; H, 7.60; N, 26.55.
4′,7-di- tert -Butyl-9a-(1-cyclohexyl-1 H -tetrazol-5-yl)-1,4,5a,6,7,8,9,9a-octahydrospiro[benzo[ e ][1,4]-diazepine-5,1′-cyclohexane]-2,3-dicarbonitrile (6c): Colorless crystals; mp >300 ˚C. IR (KBr): 3358, 3128, 3072, 2941, 2867, 2217, 1657, 1620, 1473, 1398, 1294 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 0.76 (s, 9 H, 4 × CH₃), 0.85 (s, 9 H, 4 × CH₃), 1.10-2.70 (m, 27 H, 12 × CH₂ of c-Hex and 3 × CH), 4.56 (s, 1 H, NH), 4.67 (m, 1 H, CH of c-Hex), 6.71 (s, 1 H, NH). Anal. Calcd for C₃₁H₄₈N₈: C, 69.89; H, 9.08; N, 21.03. Found: C, 69.79; H, 9.01; N, 21.00.
9 a -(1-Cyclohexyl-1 H -tetrazol-5-yl)-4′,7-diphenyl-1,4,5 a ,6,7,8,9,9 a -octahydrospiro[benzo[ e ][1,4]- diazepine-5,1′-cyclohexane]-2,3-dicarbonitrile (6d): Brown powder; mp >300 ˚C. IR (KBr): 3419, 3351, 3090, 3021, 2938, 2862, 1619, 1495, 1453, 1398 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.20 (m, 24 H, 12 × CH₂ of c-Hex), 2.43 (m, 1 H, CH), 2.64 (m, 1 H, CH), 3.10 (m, 1 H, CH), 4.79 (m, 1 H, CH of c-Hex), 5.02 (s, 1 H, NH), 7.03 (s, 1 H, NH), 7.00-7.15 (m, 3 H, ArH), 7.15-7.30 (m, 3 H, ArH), 7.32 (m, 4H, ArH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 25.1, 25.4, 28.1, 28.5, 29.2, 30.4, 33.4, 34.2, 34.9, 42.7, 43.0, 46.4, 58.1, 59.2, 106.2, 110.3, 116.1, 116.5, 126.3, 126.6, 127.0, 127.2, 128.7, 128.9, 146.8, 147.3, 161.1. MS: m/z = 421 (10) [M⁺ - 151], 309 (30), 227 (35), 184 (15), 145 (35), 117 (45), 91 (100), 55 (23). Anal. Calcd for C₃₅H₄0N₈: C, 73.40; H, 7.04; N, 19.56. Found: C, 73.33; H, 7.00; N, 19.46.
4′,7-di- tert -Butyl-9a-(1- tert -butyl-1 H -tetrazol-5-yl)-1,4,5a,6,7,8,9,9a-octahydrospiro[benzo[ e ][1,4]- diazepine-5,1′-cyclohexane]-2,3-dicarbonitrile (6e): Colorless crystals; mp 170-171 ˚C. IR (KBr): 3340, 3089, 2935, 2856, 2215, 1570, 1545, 1450 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 0.80-2.40 (m, 43 H, 7 × CH₂ of c-Hex, 9 × CH₃ and 2 × CH), 3.03 (m, 1 H, CH), 4.70 (s, 1 H, NH), 6.67 (s, 1 H, NH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 21.8, 22.1, 22.8, 26.1, 27.5, 27.8, 31.5, 32.5, 32.8, 33.0, 33.7, 46.9, 57.3, 60.6, 65.1, 104.1, 105.8, 110.6, 115.3, 163.4. Anal. Calcd for C₂₉H₄₆N₈: C, 68.74; H, 9.15; N, 22.11. Found: C, 68.62; H, 9.05; N, 22.07.



9a-(1- tert -Butyl-1 H -tetrazol-5-yl)-4′,7-diphenyl-1,4,5a,6,7,8,9,9a-octahydrospiro[benzo[ e ][1,4]- diazepine-5,1′-cyclohexane]-2,3-dicarbonitrile (6f). Brown powder; mp >300 ˚C. IR (KBr): 3406, 3236, 3160, 3040, 3021, 2926, 2850, 2219, 2194, 1634, 1544, 1443, 1366, 1316 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.20 (m, 23 H, 7 × CH₂ of c-Hex and 3 × CH₃), 2.40 (m, 1 H, CH), 2.64 (m, 1 H, CH), 3.30 (m, 1 H, CH), 4.92 (s, 1 H, NH), 6.92 (s, 1 H, NH), 7.16 (m, 3 H, ArH), 7.18 (m, 3 H, ArH), 7.32 (m, 4 H, ArH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 27.9, 28.6, 29.3, 30.8, 31.6, 33.4, 37.7, 42.9, 43.1, 48.8, 60.7, 61.2, 65.2, 105.8, 111.6, 116.6, 117.0, 126.3, 126.6, 127.1, 127.2, 128.6, 128.8, 146.9, 147.4, 163.5. Anal. Calcd for C₃₃H₃₈N₈: C, 72.50; H, 7.01; N, 20.50. Found: C, 72.42; H, 6.91; N, 20.41.
9a-(1-(2,4,4-Trimethylpentan-2-yl)-1 H -tetrazol-5-yl)-1,4,5a,6,7,8,9,9a-octahydrospiro[benzo[ e ][1,4]- diazepine-5,1′-cyclohexane]-2,3-dicarbonitrile (6g): Colorless crystals; mp 167-169 ˚C. IR (KBr): 3406, 3282, 3128, 3021, 2946, 2850, 2215, 2200, 1618, 1529, 1454, 1304 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.10 (m, 35 H, 9 × CH₂ of c-Hex, 1 × CH₂ and 5 × CH₃), 2.94 (m, 1 H, CH), 4.69 (s, 1 H, NH), 6.70 (s, 1 H, NH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 20.6, 20.7, 21.1, 21.6, 24.7, 25.4, 25.5, 25.6, 31.1, 31.2, 31.5, 48.8, 61.0, 61.8, 65.1, 105.7, 107.1, 111.2, 116.5, 163.4. Anal. Calcd for C₂₅H₃₈N₈: C, 66.63; H, 8.50; N, 24.87. Found: C, 66.58; H, 8.41; N, 24.77.
2-(1-Cyclohexyl-1 H -tetrazol-5-yl)-2,4,4-trimethyl-2,3,4,5-tetrahydro-1 H -benzo[ b ][1,4]diazepine (7a): Colorless crystals; mp 241-242 ˚C. IR (KBr): 3383, 2924, 2861, 1600, 1508, 1478, 1450, 1302, 1259 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.00 (m, 20 H, 5 × CH₂ of c-Hex, 3 × CH₃ and 1 × CH), 2.80 (AB_q, J = 13.8 Hz, 1 H, CH₂), 3.99 (br s, 1 H, NH), 4.96 (t, J = 10.9 Hz, 1 H, CH of c-Hex), 5.88 (br s, 1 H, NH), 6.40-6.50 (m, 2 H, ArH), 6.57 (dd, J = 6.8, 7.4 Hz, 1 H, ArH), 6.73 (AB_q, J = 7.6 Hz, 1 H, ArH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 25.0, 25.4, 31.6, 32.0, 32.5, 32.9, 34.3, 51.5, 53.2, 55.8, 57.9, 117.3, 119.2, 120.7, 120.9, 135.2, 136.9, 160.1. MS: m/z = 440 (75) [M]⁺, 189 (80), 173 (100), 133 (80), 90 (10), 55 (15). Anal. Calcd for C₁₉H₂₈N₆: C, 67.03; H, 8.29; N, 24.68. Found: C, 69.90; H, 8.22; N, 24.60.
4-(1-Cyclohexyl-1 H -tetrazol-5-yl)-2,2,4-trimethyl-7-nitro-2,3,4,5-tetrahydro-1 H -benzo[ b ][1,4]diazepine (7b): Red powder; mp 196-198 ˚C. IR (KBr): 3400, 3374, 2928, 2859, 1644, 1594, 1530, 1461, 1404, 1309 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.10 (m, 20 H, 5 × CH₂ of c-Hex, 3 × CH₃ and 1 × CH), 3.09 (AB_q, J = 13.2 Hz, 1 H, CH₂), 4.67 (m, 1 H, CH of c-Hex), 5.75 (br s, 1 H, NH), 6.50 (br s, 2 H, ArH and AB_q, J = 9.3 Hz, ArH), 6.38 (AB_q, J = 7.7 Hz, 1 H, ArH), 7.76 (br s, 1 H, NH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 24.7, 24.9, 25.2, 31.0, 32.5, 33.0, 33.6, 34.4, 49.2, 53.8, 55.8, 57.7, 112.9, 116.8, 117.9, 134.7, 138.9, 144.2, 159.6. MS: m/z = 385 (50) [M]⁺, 234 (65), 218 (100), 177 (50), 132 (45), 83 (10), 55 (35). Anal. Calcd for C₁₉H₂₇N₇O₂: C, 59.20; H, 7.06; N, 25.44. Found: C, 59.07; H, 7.01; N, 25.34.
(4-(1-Cyclohexyl-1 H -tetrazol-5-yl)-2,2,4-trimethyl-2,3,4,5-tetrahydro-1 H -benzo[ b ][1,4]diazepin-7-yl)(phenyl)methanone (7c): Yellow powder; mp 293-295 ˚C. IR (KBr): 3349, 3084, 3040, 2970, 2935, 2850, 1631, 1570, 1492, 1402, 1342, 1301 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.28 (br s, 3 H, CH₃), 1.32 (br s, 3 H, CH₃), 1.44 (br s, 3 H, CH₃), 1.00-2.00 (m, 11 H, 5 × CH₂ of c-Hex and 1 × CH), 3.08 (AB_q, J = 13.5 Hz, 1 H, CH₂), 4.69 (m, 1 H, CH of c-Hex), 5.16 (br s, 1 H, NH), 6.30 (br s, 1 H, NH), 6.47 (AB_q, J = 8.1 Hz, 1 H, ArH), 6.83 (AB_q, J = 7.5 Hz, 1 H, ArH), 7.41 (s, 1 H, ArH), 7.45-7.60 (m, 5 H, ArH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 24.9, 25.0, 25.1, 31.2, 32.4, 33.1, 33.4, 34.5, 49.9, 53.5, 55.8, 57.6, 118.1, 119.2, 123.9, 127.7, 128.6, 129.2, 131.6, 135.1, 139.3, 141.8, 160.0, 194.2. Anal. Calcd for C₂₆H₃₂N₆O: C, 70.24; H, 7.26; N, 18.90. Found: C, 70.15; H, 7.20; N, 18.81.
4a′-(1-Cyclohexyl-1 H -tetrazol-5-yl)-7′-nitro-1′,2′,3′,4′,4a′,5′,10′,11a′-octahydrospiro[cyclohexane-1,11′-dibenzo[ b , e ][1,4]diazepine] (7d): Red powder; mp >300 ˚C. IR (KBr): 3394, 3368, 3065, 2932, 2857, 1594, 1524, 1493, 1467, 1327, 1272 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.10 (m, 28 H, 14 × CH₂ of c-Hex), 2.86 (m, 1 H, CH), 4.55 (m, 1 H, CH of c-Hex), 5.08 (br s, 1 H, NH), 6.39 (br s, 1 H, NH), 6.65 (AB_q, J = 8.7 Hz, 1H, ArH), 7.37 (AB_q, J = 6.6 Hz, 1 H, ArH), 7.72 (br s, 1 H, ArH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 21.2, 21.3, 21.5, 24.8, 24.9, 25.2, 25.4, 25.8, 31.1, 34.7, 49.0, 57.8, 58.4, 58.7, 59.4, 111.0, 115.6, 118.4, 137.6, 140.2, 141.8, 162.3. Anal. Calcd for C₂₅H₃₅N₇O₂: C, 64.49; H, 7.58; N, 21.06. Found: C, 64.39; H, 7.48; N, 21.01.
{4a′-(1-Cyclohexyl-1 H -tetrazol-5-yl)-1′,2′,3′,4′,4a′,5′,10′,11a′-octahydrospiro[cyclohexane-1,11′-dibenzo[ b , e ][1,4]-diazepine]-7′-yl}(phenyl)methanone (7e): Yellow powder; mp >300 ˚C. IR (KBr): 3381, 3354, 2926, 2856, 1625, 1575, 1500, 1445, 1398, 1336 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.10 (m, 28 H, 14 × CH₂ of c-Hex), 2.86 (m, 1 H, CH), 4.59 (m, 2 H, CH of c-Hex and NH), 6.13 (br s, 1 H, NH), 6.60 (AB_q, J = 7.7 Hz, 1 H, ArH), 6.83 (AB_q, J = 8.1 Hz, 1 H, ArH), 7.38 (s, 1 H, ArH), 7.50-7.60 (m, 5 H, ArH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 21.4, 21.5, 25.0, 25.3, 25.5, 25.9, 32.0, 32.9, 34.8, 37.8, 49.6, 57.6, 58.4, 58.9, 117.7, 119.7, 122.8, 128.7, 129.3, 131.7, 137.7, 139.2, 139.4, 162.7, 194.3. Anal. Calcd for C₃₂H₄₀N₆O: C, 73.25; H, 7.68; N, 16.02. Found: C, 73.14; H, 7.58; N, 15.93.
2-(1-Cyclohexyl-1 H -tetrazol-5-yl)-2,4,4,7-tetramethyl-2,3,4,5-tetrahydro-1 H -benzo[ b ][1,4]diazepine (7f): White powder; mp 202-204 ˚C. IR (KBr): 3381, 3306, 2928, 2862, 1600, 1525, 1478, 1451, 1398, 1309 cm^-¹. ^¹H NMR (300.13 MHz, DMSO-d ₆): δ = 1.00-2.10 (m, 23 H, 5 × CH₂ of c-Hex, 4 × CH₃ and 1 × CH), 2.78 (AB_q, J = 14.1 Hz, 1 H, CH₂), 4.96 (m, 1 H, CH of c-Hex), 5.69 (br s, 1 H, NH), 6.37 (br s, 1 H, ArH), 6.38 (AB_q, J = 7.7 Hz, 1 H, ArH), 6.56 (br s, 1 H, NH), 6.62 (AB_q, J = 7.7 Hz, 1 H, ArH). ^¹³C NMR (75.47 MHz, DMSO-d ₆): δ = 20.6, 20.8, 25.1, 25.4, 31.5, 31.6, 31.8, 32.0, 32.3, 32.9, 34.3, 51.6, 53.1, 55.8, 57.9, 117.7, 121.2, 121.4, 127.8, 134.4, 135.3, 160.1. MS: m/z = 354 (80) [M]⁺, 203 (80), 187 (100), 147 (80), 55 (23). Anal. Calcd for C₂₀H₃₀N₆: C, 67.76; H, 8.53; N, 23.71. Found: C, 67.69; H, 8.45; N, 23.61.